CA2090942C - Anti-tumour compounds containing quinazoline and tetrazole rings - Google Patents

Anti-tumour compounds containing quinazoline and tetrazole rings Download PDF

Info

Publication number
CA2090942C
CA2090942C CA002090942A CA2090942A CA2090942C CA 2090942 C CA2090942 C CA 2090942C CA 002090942 A CA002090942 A CA 002090942A CA 2090942 A CA2090942 A CA 2090942A CA 2090942 C CA2090942 C CA 2090942C
Authority
CA
Canada
Prior art keywords
prop
ynyl
dihydroquinazolin
oxo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002090942A
Other languages
English (en)
French (fr)
Other versions
CA2090942A1 (en
Inventor
Stephen John Pegg
James Michael Wardleworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Syngenta Ltd
Original Assignee
Zeneca Ltd
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd, British Technology Group Ltd filed Critical Zeneca Ltd
Publication of CA2090942A1 publication Critical patent/CA2090942A1/en
Application granted granted Critical
Publication of CA2090942C publication Critical patent/CA2090942C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Golf Clubs (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Dental Preparations (AREA)
CA002090942A 1992-03-11 1993-03-03 Anti-tumour compounds containing quinazoline and tetrazole rings Expired - Fee Related CA2090942C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9205320.6 1992-03-11
GB929205320A GB9205320D0 (en) 1992-03-11 1992-03-11 Anti-tumour compounds

Publications (2)

Publication Number Publication Date
CA2090942A1 CA2090942A1 (en) 1993-09-12
CA2090942C true CA2090942C (en) 2000-02-08

Family

ID=10711936

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002090942A Expired - Fee Related CA2090942C (en) 1992-03-11 1993-03-03 Anti-tumour compounds containing quinazoline and tetrazole rings

Country Status (22)

Country Link
US (1) US5955463A (Direct)
EP (1) EP0562734B1 (Direct)
JP (1) JP3160111B2 (Direct)
KR (1) KR100221011B1 (Direct)
AT (1) ATE131823T1 (Direct)
AU (1) AU659277B2 (Direct)
CA (1) CA2090942C (Direct)
CZ (1) CZ281811B6 (Direct)
DE (1) DE69301048T2 (Direct)
DK (1) DK0562734T3 (Direct)
ES (1) ES2081178T3 (Direct)
FI (1) FI108793B (Direct)
GB (2) GB9205320D0 (Direct)
GR (1) GR3018501T3 (Direct)
HK (1) HK21297A (Direct)
HU (1) HU211127A9 (Direct)
IL (1) IL104984A (Direct)
NO (1) NO301543B1 (Direct)
NZ (1) NZ247122A (Direct)
RU (1) RU2111209C1 (Direct)
TW (1) TW223635B (Direct)
ZA (1) ZA931447B (Direct)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223352D0 (en) * 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
CA2222545A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
EP1049786A2 (en) 1998-01-21 2000-11-08 Sugen, Inc. Human orthologues of wart
DE69926742T2 (de) 1998-04-14 2006-06-14 Sugen Inc Ste20-verwandte proteinkinasen
US6235213B1 (en) * 1998-05-18 2001-05-22 Micron Technology, Inc. Etching methods, methods of removing portions of material, and methods of forming silicon nitride spacers
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
RU2256654C2 (ru) * 1999-01-22 2005-07-20 Кирин Бир Кабусики Кайся Хинолиновые и хиназолиновые производные
BRPI0008128B8 (pt) * 1999-02-10 2021-05-25 Astrazeneca Ab derivados de quinazolina, composições farmacêuticas contendo os mesmos, e, uso dos mesmos como inibidores de angiogênese
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
JP2003512838A (ja) 1999-10-22 2003-04-08 ファルマシア・アンド・アップジョン・カンパニー ショウジョウバエｇタンパク質結合レセプター、核酸、およびそれに関連する方法。
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
DE60134224D1 (de) 2001-08-10 2008-07-10 Ford Global Tech Inc Ansaugkrümmer
BRPI0212215B8 (pt) 2001-08-31 2021-07-27 Btg Int Ltd compostos de ciclopenta[g]quinazolina anticâncer, uso dos mesmos para o tratamento de câncer e composição farmacêutica compreendendo dito composto
ES2373644T3 (es) 2001-08-31 2012-02-07 Btg International Limited Uso de derivados de ciclopenta[g]quinazolina para el tratamiento del c�?ncer.
ATE387451T1 (de) * 2002-11-04 2008-03-15 Astrazeneca Ab Chinazolinderivate als src- tyrosinkinaseinhibitoren
GB0317631D0 (en) * 2003-07-28 2003-08-27 Btg Int Ltd Synthetic method
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
MXPA06009019A (es) * 2004-02-18 2007-03-08 Astrazeneca Ab Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotropico.
EP1962903B1 (en) 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069468D1 (en) * 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
JPS5692876A (en) * 1979-12-19 1981-07-27 Nat Res Dev Anticancerous quinazoline derivative
GB8513754D0 (en) * 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
US5187167A (en) * 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4725687A (en) * 1986-04-28 1988-02-16 Southern Research Institute 5-methyl-5-deaza analogues of methotrexate and N10 -ethylaminopterin
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
US4999424A (en) * 1988-11-10 1991-03-12 The Pennsylvania State University GAR transformylase inhibitor
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US5252573A (en) * 1988-12-15 1993-10-12 Imperial Chemical Industries Plc Anti-tumor agents
IL98167A0 (en) * 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
US5145854A (en) * 1991-11-27 1992-09-08 Nair Madhavan G 1-formyl-5,8,10-trideazafolates

Also Published As

Publication number Publication date
HK21297A (en) 1997-02-27
DE69301048D1 (de) 1996-02-01
DK0562734T3 (da) 1996-05-06
CZ36293A3 (en) 1994-01-19
EP0562734B1 (en) 1995-12-20
ES2081178T3 (es) 1996-02-16
TW223635B (Direct) 1994-05-11
CZ281811B6 (cs) 1997-02-12
DE69301048T2 (de) 1996-05-15
FI108793B (fi) 2002-03-28
CA2090942A1 (en) 1993-09-12
FI931067L (fi) 1993-09-12
EP0562734A1 (en) 1993-09-29
IL104984A (en) 1998-01-04
IL104984A0 (en) 1993-07-08
NO301543B1 (no) 1997-11-10
AU659277B2 (en) 1995-05-11
GR3018501T3 (en) 1996-03-31
AU3378293A (en) 1993-09-16
KR100221011B1 (ko) 1999-09-15
GB9304807D0 (en) 1993-04-28
NO930881D0 (no) 1993-03-10
GB2264946B (en) 1995-05-17
JPH06279438A (ja) 1994-10-04
HU211127A9 (en) 1995-10-30
JP3160111B2 (ja) 2001-04-23
GB9205320D0 (en) 1992-04-22
ATE131823T1 (de) 1996-01-15
ZA931447B (en) 1993-09-13
NZ247122A (en) 1995-07-26
KR930019667A (ko) 1993-10-18
US5955463A (en) 1999-09-21
FI931067A0 (fi) 1993-03-10
RU2111209C1 (ru) 1998-05-20
GB2264946A (en) 1993-09-15
NO930881L (no) 1993-09-13

Similar Documents

Publication Publication Date Title
CA2090942C (en) Anti-tumour compounds containing quinazoline and tetrazole rings
US5081124A (en) Method of producing antitumor effect using quinazolin-4-one derivatives
EP0284338B1 (en) Anti-tumour agents
DE69522717T2 (de) Chinazolinderivate
CA2121816A1 (en) Substituted heterocycles as angiotensin ii antagonists
US5187167A (en) Pharmaceutical compositions comprising quinazolin-4-one derivatives
AP218A (en) Benzoquinazole derivatives and pharmaceutical compounds thereof.
GB2271111A (en) Quinazoline derivatives
EP0318225A2 (en) 6-Aryl aminomethyl quinoline derivatives and their use as anti-tumour agents
US5789417A (en) Tricyclic compounds with pharmaceutical activity
US5747499A (en) Anti-cancer compounds
EP0339976A1 (en) Anti-tumour agents
US5252573A (en) Anti-tumor agents
WO1995009158A1 (en) Tricyclic derivatives
GB2272217A (en) Anti-cancer cyclopentaquinazolines
HK1141804A (en) Quinazoline derivatives
HK1042083A (en) Quinazoline derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed